We’re continuing to tackle payment paradigms for corneal tissue reimbursements
that are forcing surgeons to provide fewer corneal transplants than they have in the past.
To ensure patients have access to a high standard of care
, SightLife, our parent organization, analyzed trends
in Medicare insurance claims data and found that 45 percent of the time hospital outpatient departments did not submit any charge to Medicare for corneal tissue. Failure to claim Medicare reimbursement can lead hospitals to conclude that corneal transplant procedures are not cost effective, distorting the total costs of corneal graft procedures and causing them to limit corneal surgeries.
We’re leading the way in working with payers, national associations and healthcare policy makers
to develop accessible and affordable solutions for corneal transplant procedures.
Tell us how we can help